Adlai Nortye (ANL) Income towards Parent Company (2024)
Adlai Nortye's (ANL) quarterly Income towards Parent Company came in at -$10000.0 in Q4 2024.
Adlai Nortye (ANL) Income towards Parent Company (2024) Analysis & Trends
Adlai Nortye (ANL) has 1 years of Income towards Parent Company data on file, last reported at -$10000.0 in Q4 2024.
- On a quarterly basis, Income towards Parent Company changed N/A year-over-year to -$10000.0 in Q4 2024; TTM through Dec 2025 was -$10000.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at -$35.5 million, up 31.5% from the prior year.
- Income towards Parent Company for Q4 2024 stood at -$10000.0.
- Over the last five years, Income towards Parent Company for ANL reached as high as -$10000.0 in Q4 2024 and fell as low as -$10000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Adlai Nortye | 1.16 Bn | 1.15 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -10,000.00 |